Search
Close this search box.
Search
Subscribe
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)

Stock Piper AI Index

Subscribe
Search
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)
Hang Seng
17,093.50
(3.05%)
Dow Jones
39,023.71
(0.66%)
Nikkei 225
38,797.51
(-0.06%)
FTSE 100
7,747.81
(1.02%)
USD/AUD
0.6617
(-0.2%)
Bitcoin
71,640.19
(-1.56%)
Oil
78.00
(0.57%)
Gold
2,163.90
(-0.1%)
Lithium
46.11
(4.37%)
Iron Ore
109.15
(1.77%)

Recce Pharmaceuticals (ASX: $RCE) doses first participants in uti/urosepsis trial

  • Author: Stock Piper

Recce Pharmaceuticals (ASX: $RCE) Phase I/II UTI/Urosepsis Clinical Trial Update


Recce Pharmaceuticals Limited (ASX: $RCE) has successfully dosed the first male and female participants in the next cohort with RECCE® 327 (R327) at 4,000mg intravenously (I.V.) at a fast infusion rate of 20-minutes in its Phase I/II UTI/Urosepsis clinical trial. The company has explored multiple infusion times of R327 within this clinical trial, including 15-mins, 20-mins, 30-mins, and 45-mins. This marks the highest dose (4,000mg) tested in participants in this trial with Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples.

Executive Commentary on Phase I/II UTI/Urosepsis Clinical Trial Progress


The full efficacious potential of R327 via I.V. administration will be made available at the completion of this clinical trial in line with study protocol.

Summary of Recce Pharmaceuticals (ASX: $RCE) Phase I/II UTI/Urosepsis Clinical Trial Update


Recce Pharmaceuticals Limited (ASX: $RCE) has successfully dosed the first male and female participants in the next cohort with RECCE® 327 (R327) at 4,000mg intravenously (I.V.) at a fast infusion rate of 20-minutes in its Phase I/II UTI/Urosepsis clinical trial. The company has explored multiple infusion times of R327 within this clinical trial, including 15-mins, 20-mins, 30-mins, and 45-mins. This marks the highest dose (4,000mg) tested in participants in this trial with Minimum Inhibitory Concentration (MIC) activity against bacteria already identified among existing clinical samples. The full efficacious potential of R327 via I.V. administration will be made available at the completion of this clinical trial in line with study protocol.

RECCE PHARMACEUTICALS LTD
RCE | ASX | Health Care
0.4750.005(+1.06%)
At close 05/07 (AEDT)
Market cap
$95.9M
Volume
284,448
DY Yield
0
PE Ratio
0
52 Week Range
0.41 - 0.777
1YR Return
N / A

Share to Social
0 Comments
Inline Feedbacks
View all comments

$DGL

$DGL

DGL Group (ASX: $DGL) acquires Australian Petro Chemical Storage

$ICG

$ICG

Inca Minerals (ASX: $ICG) targets new generation of tier-1 mineral discoveries in australia

ASX News, First
& Fast.

By clicking Subscribe, you agree to our Terms & Conditions

ASX News, First And Fast.

By clicking Subscribe, you agree to our Terms & Conditions

© 2024 Stock Piper. All rights reserved

Join FREE Newsletter

ASX News, First And Fast.

Get all the latest market updates straight to your inbox.

By clicking Subscribe, you agree to our Terms & Conditions

Stock Piper AI Index Coming Soon!

Join our Newsletter to gain exclusive insight and be notified once we are live.

By clicking Subscribe, you agree to our Terms & Conditions